The administration of interleukin-2 (IL-2) may induce complete remissions in acute myelogenous leukemia (AML) patients with a low proportion of residual bone marrow (BM) blasts. To confirm this preliminary observation, we treated 14 AML patients with advanced disease and with a residual BM blastosis that ranged between 7% and 24% with repeated 5-day cycles of high-dose recombinant IL-2 administered by daily continuous intravenous infusion. Patients who responded have been subsequently submitted to a monthly maintenance scheme with subcutaneous IL-2 at lower doses. While using this schedule and closely monitoring clinical and laboratory conditions, side effects were acceptable NTERLEUKIN-2 (IL-2) is a cytokine capable of amplifying spontaneous cytotoxicity' and of inducing lymphokine activated killer (LAK) activity.' Extensive clinical trials have shown that IL-2-based immunotherapy may induce objective regressions in a proportion of human solid tumors."' Several groups have shown that acute leukemia cells of both myeloid and lymphoid origin may be susceptible to the lytic action of LAK cells6-8 and that patients in complete remission (CR) often show a good LAK activity.' Furthermore, LAK cells and IL-2 alone may block the growth of human leukemic cells in immunosuppressed nude mice.8*10 Although leukemic blasts may express the IL-2 receptor a and/or p chains,'','* IL-2 may induce a proliferative stimulus on the neoplastic population in only a minority of patients."
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Based on these studies, in 1988 we started to use IL-2 by continuous infusion in the management of hematologic malignancies with particular emphasis on acute myelogenous leukemia (AML) in advanced phase. Our earlier studies, designed to explore the feasibility and toxicity of IL-2 administration in acute leukemias, showed that IL-2 can be administered to acute leukemia patients. In refractory AML cases with a low proportion of detectable residual marrow blasts, IL-2 may induce the disappearance of the leukemic population."-16." To confirm and expand these encouraging preliminary observations, we have studied a further series and no toxic deaths recorded. Eight of the 14 patients treated with high-dose IL-2 obtained a complete remission (CR). Five remain in persistent CR (four in third CR and one in fourth CR) after a median follow-up time of 32 months (14, 30, 32, 33, and 68 months, respectively). In all five patients, the IL-2-induced remission is the longest in the natural history of the disease. These findings show that IL-2 displays an antileukemic effect in AML with limited residual disease, and suggest that IL-2 should be considered a therapeutic option for resistant or relapsed AML patients. of AML patients with advanced disease and with a limited bone marrow (BM) blastosis who have been treated with high-dose IL-2. We hereby report the clinical outcome of 14 consecutive AML patients who have entered the study, and in particular, the long-term follow-up of the responsive patients that has ranged between 14 and 68 months after the initiation of IL-2.
PATIENTS AND METHODS

Patients
Fourteen patients have been enrolled in this study. All were affected by primary AML, diagnosed cytologically and confirmed by cytochemistry and immunophenotypic analysis. The inclusion criteria were: (1) relapsed or refractory leukemia with more than 5% and less than 30% BM blasts confirmed by at least three marrow aspirates within 1 month (each marrow preparation was seen by at least three independent observers); (2) inelegibility for further intensive chemotherapy programs; (3) absence of central nervous system (CNS) involvement, major organ failure, or active infectious processes; and (4) written informed consent (obtained from parents in patients less than 18 years old).
The characteristics of the patients are shown in Table I . Median age was 30 years (range 8 to 55); seven patients were males. According to the French-American-British classification, six patients were M4; five patients, M2; two patients, M1; and one patient, M5. The mean percentage of BM blasts was 13% (range, 7% to 24%).
Standard Chemotherapy had been stopped at least 4 weeks before IL-2, and steroid treatment at least 2 weeks before starting IL-2. Three patients were refractory to two different induction regimens; 1 l patients were in hematologic relapse (1 in first, 6 in second, 3 in third, and 1 in fourth) refractory to chemotherapy; 2 of them had also suffered from a previous CNS relapse.
During the course of their disease, all patients received different chemotherapy regimens including anthracyclines and citosine-arabinoside (ARA-C) at high or intermediate doses. Four patients also underwent an autologous BM transplantation (BMT) (three in first and one in third CR), and one patient received two autologous BMT (one in first and one in second CR, respectively).
IL-2
The first five patients were treated with Glaxo IL-2 (Glaxo, Geneva, Switzerland), whereas the others received EuroCetus IL-2 (Proleukin; EuroCetus, Amsterdam, The Netherlands).
Gfuxo IL-2. Each vial (100 pg), with a specific activity of 1.5 x IOo Ulmg, was reconstituted with 1 mL of sterile water and the total IL-2 dose, dissohed in a saline solution containing 20% of human albumin to a total volume of 10 mL, was infused using a B.
Braun microinjection pump (Melsungenag, Germany) over a period of 24 hours. Proleukin. Each vial (1 mg), containing 3 X lo6 Cetus U (18 x lo6 IU), was reconstituted with 1.2 mL of sterile water and the total IL-2 dose, dissolved in a 5% glucose solution to a final volume of 10 mL, was infused with the same modalities described above.
Treatment Plan
IL-2 was administered intravenously by 24-hour continuous infusion for S days, using a daily dose-escalating protocol. IL-2 infusion was then repeated after a rest of at least 72 hours starting from the maximum tolerated dose, for a total of four cycles. The maximum dose to be reached with Glaxo IL-2 was 900 pg/m2/d, starting from 100 pg/m2/d, whereas the highest Proleukin dose was 18 X IO6 I U / m2/d, starting from 8 X lo6 IU/m*/d.
Patients who responded to IL-2 entered a maintenance program consisting of monthly 5-day courses of lower doses of IL-2 administered on an outpatient basis; in the first three patients, a 6-hour continuous intravenous infusion route was used, whereas in the later patients, IL-2 was given subcutaneously. Glaxo maintenance doses were 100 pg/m2 on day 1 and 200 &m2 for four days after, whereas Proleukin doses were 4 X IO6 IU/mZ on day 1 and 8 X lo6 IU/m2 on days 2 through S (Fig 1) . After the first year, maintenance was administered every other month at a lower dose (4 X lo6 IU/m2/d) and continued in all responding patients until relapse. In patients receiving maintenance IL-2, no other treatment was planned until relapse.
Supportive Care and Monitoring
During the induction cycles, all patients were nursed in double rooms with the relatives' assistance. Patients had a single-lumen central catheter and received prophylactic therapy with acetaminophen 300 mg/m2 by mouth every 6 hours, ascorbic acid 1 g/d, allopurinol 300 mg/m2/d, and ranitidine intravenously 300 mg/d. Cotrimoxazole was also given at a dose of 480 mg twice daily. Intravenous broad-spectrum antibiotics were used only in the presence of a documented infection. Platelet transfusions were given when the platelet count was lower than 20 X io9& body temperature was greater than 3 8 T , or bleeding was present. Packed red blood cells (RBCs) were transfused when hemoglobin was lower than 11 g/dL. Standard peripheral blood (PB) studies, including complete counts, hepatic and renal function tests, and electrolyte determinations, were performed daily during the induction treatment; echocardiographic monitoring of cardiac function was performed at least before each induction cycle.
BM evaluations were performed in all patients before starting IL-2 and at the end of each induction cycle. A documented progression of disease was mandatory for the discontinuation of IL-2 treatment.
Meperidine for chills, loperamide for diarrhea, antihistaminics for itching, and benzodiazepine for anxiety were used as needed. Initial support of hypotension and oliguria consisted of rapid infusion of human albumin and colloid solutions; low-dose dopamine (2 to S pg/kg/min) was added if volume replacement was not sufficient. Furosemide was given only in the case of persistent oliguria with a documented normal central venous pressure.
Toxicity was defined according to the World Health Organization (WHO) grading system.'' Doses of IL-2 were not increased when simultaneous grade 2 toxicities were present, whereas IL-2 was stopped in the presence of side effects that were considered either acutely life-threatening or likely to become life-threatening on the basis of the known cumulative effects of additional doses.
During treatment with IL-2 and until patients went off-study either for progression or relapse, no other chemoradiotherapy or biologic therapy was installed.
Immunologic Activation
Mononuclear PB and BM cells were obtained after fractionation on a Lymphoprep gradient (Nycomed As, Oslo, Norway). The cells recovered from the interface were washed twice and resuspended in RPMI 1640 (Flow Laboratories, Opera, Italy) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Flow). The expression of Leu-l 1 (CD16) and the IL-2 receptor a chain (CD25) (Becton Dickinson, Mountain View, CA) was monitored using a FACScan flow cytometer (Becton Dickinson).
LAK cells were generated by incubating mononuclear cells at the concentration of 1.5 X 106/mL in RPMI 1640 supplemented with 10% heat-inactivated FBS, in the presence of 100 U/mL of recombinant IL-2 (rIL-2) (Glaxo Institute for Molecular Biology) for 7 days at 37°C with 5% CO2 in humidified air. To assess whether the administration of IL-2 was capable of inducing in vivo the generation of LAK cells, the lytic activity against Raji cells was also tested on PB and marrow lymphocytes before and after treatment in the absence of any further in vitro preincubation with IL-2. The natural killer (NK) activity was measured using the classic 5'Cr release assay against the K562 cell line as previously described in detail.''' The results reported always referred to a final effector:target ratio of 100: I .
Evaluation qf Response
Response to the 1L-2 induction treatment was evaluated at the end of the last cycle. A CR was defined as a cellular marrow with less than 5% blasts, a normalization of PR counts and a disappearance of any clinical features related to the leukemia that persisted more than 1 month.
BM aspirates have also been performed monthly before each maintenance cycle to confirm the persistence of response.
A patient was defined in relapse when a BM blastosis greater than 25% was observed in two consecutive BM aspirates performed after a l-week interval.
RESULTS
Toxicity
The usual IL-2-related side effects (ie, fever, nausea and/ or vomiting, and hemodynamic and metabolic toxicities) were recorded in all patients. Figure 2 shows WHO side effects greater than grade 2 that occurred at least once during induction treatment. The administration of IL-2 was adjusted according to toxicity. The median percentage of IL-2-planned dose administered is shown in Incidence ("A) For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From
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effects, no IL-2-related deaths occurred during the induction period. During maintenance therapy, only mild fever (WHO grade 2), fatigue, and occasional nausea were observed.
Hematologic Modifications
During the administration of IL-2, the proportion of lymphocytes always decreased, whereas a rebound absolute lymphocytosis was observed in all cases 24 to 48 hours after stopping therapy. The mean lymphocyte count before IL-2 was 1.06 X 109L (range, 0.2 to 1.8) and the peak after the last induction cycle was 6.44 X 109L (range, 2.2 to 9.1). The subsequent IL-2 course was often started when a high lymphocyte count was still present, and lymphopenia occurred within 48 to 72 hours from the start of IL-2. The neutrophil and, mainly, eosinophil counts increased during the cycles, whereas platelets decreased slowly during the entire induction therapy and reached the minimum at the end of the last cycle in all but one patient.
During maintenance treatment, a progressive increase in eosinophils was present during the course of treatment, and a lymphocytosis has been often observed after 24 to 48 hours from the end of IL-2. These changes were less pronounced compared with those observed during the induction cycles.
Clinical Results
By the end of the induction cycles, a CR was achieved in 8 of the 14 patients treated. One (no. 14), received IL-2 in first hematologic relapse that occurred after a first CR obtained with a second line treatment and lasted 4 months. This patient was treated with 9% BM blasts and received three induction cycles because of toxicity (fever, hypercreatininemia). For this reason, maintenance was performed with a very low dose (4 X 106/IU/d total dose). Fourteen months after starting L-2, the patient is in persistent CR.
Five patients received IL-2 in second relapse. All had been treated with the current chemotherapy protocol to obtain the first CR (anthracyclines plus ARA-C in induction and consolidation), and one of them also received an autograft; the median first CR duration was 11 months (range, 5 to 16 months). After achieving their third CR with IL-2, they were all started on the monthly IL-2 maintenance protocol. Two of the five patients are still in CR and on maintenance after 30 and 32 months, whereas three relapsed after 5, 5, and 9 months, respectively; this last patient (no. 2) was then reinduced in fourth CR with low-dose ARA-C and retreated with low-dose maintenance L-2. Patient no. 1 received IL-2 in third relapse after a short third CR duration (3 months). This patient also underwent two autologous BMT, one in first and one in second CR. Starting from the third year, IL-2 was reduced to 8 X lo6 IU/d total dose every 3 months. Sixtyeight months after starting IL-2, the patient remains in persistent fourth CR.
The last patient (no. 5 ) received IL-2 in fourth relapse; he had undergone an autologous BMT in third CR. The fifth CR obtained with IL-2 is still lasting, under IL-2 maintenance, 33 months later.
Six patients did not respond to IL-2 and went off-study (three were primary refractory to more than two induction regimens, one was in second and two were in third relapse). 
1
Immunologic Studies
Reevaluation of the immune status of the patients at the end of the induction cycles of IL-2 showed a marked phenotypic and functional activation, both on circulating and on BM lymphocytes. The results obtained are shown in Fig 3, A and B. Lymphocyte activation was documented by the increase in the expression of the a chain of the E-2 receptor. The expansion of the cytotoxic compartment was shown phenotypically on the basis of CD16 expression. Functionally, the administration of IL-2 induced a notable enhancement of NK and LAK activity, as well as the generation of endogenous LAK effectors.
DISCUSSION
The results of the present study confirm on a larger series of patients with an adequate follow-up the preliminary evidence of an antileukemic efficacy of L -2 in AML patients with a relatively small proportion of residual marrow blasts.
Using IL-2 alone, we could successfully induce a CR in 57% of the treated patients (8/14). All had advanced disease, were heavily pretreated, had a proportion of residual marrow blasts that ranged between 7% and 24%, and had a low For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From 2162 MELON1 ET AL probability of obtaining a new and durable response with further conventional therapeutic approaches. So far, in four of the eight patients, the IL-2-induced CR has lasted over 2.5 years. One such patient persists in fourth CR more than 5.5 years after starting IL-2. A fifth patient remains in persistent remission 14 months after starting IL-2. For all five cases, the IL-2-induced CR is the longest in the clinical history of each patient. Because, at the time of starting IL-2, these five patients were in refractory second or third relapse, their prognosis with conventional treatment was extremely poor. Thus, it appears highly likely that the persistent CR can be ascribed to the administration of IL-2. Though the possibility that IL-2 may trigger a proliferative signal on myeloid blasts may be of concern:' it is worth noting that IL-2 did not induce progression of disease in any of the 14 patients treated. These findings are in agreement with earlier preclinical data'' and with the recent evidence that human myeloid and lymphoid acute leukemia cells transduced with the IL-2 gene do not modify their proliferative and growth features.*'
With regard to feasibility and toxicity, the continuous intravenous daily dose-escalating protocol allows the doses of IL-2 to be modulated on the basis of the individual tolerance of each patient, enabling each patient to receive the highest tolerated dose without the risk of overtreatment. This appears to be a relevant issue, both in terms of individual compliance and because compelling evidence of a dose-dependent activity of IL-2 is still lacking. In addition to the well-known side effects commonly observed in IL-2-treated individuals, six leukemic patients (43%) showed a documented infection, with multiple-positive blood cultures, mainly caused by Staphylococci. These occurred only during the high-dose IL-2 administration. This relatively high incidence of grampositive septicemia, which is in agreement with previous reports,22 prompted to implement for the subsequent patients treated with IL-2 a prophylactic protocol for gram-positive organs (teicoplanine) as first antibiotic approa~h.~' Unlike the high-dose induction cycles, the maintenance schedule has been feasibile on an outpatient basis, with doses of IL-2 that can be considered as intermediate (up to 8 X 10' IU/ m2/d); side effects have been moderate and controllable, and in no case was hospitalization required.
The clinico-hematologic changes included neutrophilia with eosinophilia during the infusion of IL-2, whereas 24 to 48 hours after the end of each induction cycle, an increase in the white blood cell count with an absolute lymphocytosis is observed. The morphologic changes occur also in the marrow. These are likely to be contributed by the different cytokines that are known to be released in vivo in patients with solid tumors or hematologic malignancies treated with ILdetectable modifications of the PB picture-with an increase in the lymphocyte count, granular lymphocytes, and eosinophils-could be documented at the end of the administration, suggesting that IL-2, even at lower doses, may still exert a certain degree of activity.
The immunologic studies extended previous observatered during the induction cycles produced a marked activa-224.25 (and personal data). During maintenance, limited but tions19.26.27 and showed that the high doses of XL-2 administion of the immune system of the host both in PB and BM lymphocytes. This was documented by the expression of the IL-2 receptor and by a twofold to 10-fold amplification of the NK and LAK compartments, which included the generation of endogenous LAK effectors. It is worth noting that these phenotypic and functional changes are much more evident compared with those observed in acute leukemia patients with a larger marrow blastosis." However, despite the marked immunologic modifications, no clearcut correlation between clinical response, outcome, and in vitro data could be established. Taken together, the results of this study indicate that (1) high doses of IL-2 can be safely administered to AML patients in advanced phase of their disease if clinical and laboratory conditions are closely monitored; (2) complete and prolonged remissions may be obtained in patients with limited disease; (3) IL-2 induces a marked circulating and marrow immune activation in this category of patients; and (4) subcutaneous maintenance treatment with IL-2 can also be safely performed on an outpatient basis for prolonged periods (up to over 5 years) without sequalae.
One relevant but as of yet unclarified issue is the heterogeneous clinical responses observed in patients with a similar clinico-hematologic picture. It is tempting to hypothesize the presence of specific antitumor cytotoxic T lymphocytes (CTLs) in some cases that may be amplified by the administration of IL-2. In experimental turn or^,^^^^^ and more recently in human rnelan~ma,~' it has been shown that the IL-2 released constitutively by IL-2 gene-transduced tumor cells is capable of generating CTLs directed specifically against the autologous tumor. Thus, it is conceivable that this may have occurred in a proportion of acute leukemia patients treated with exogenous IL-2.
In conclusion, these data have documented the antileukemic effect of IL-2 alone in AML and suggest that IL-2 should be considered a therapeutic option for AML patients with a proportion of residual chemoresistant blasts.
The possibility of a major efficacy of rIL-2 in patients treated with less advanced disease before the development of chemotherapy resistance should be also considered. AML patients in CR, both after ABMT and after chemotherapy, who are undergoing randomized trials, will probably contribute to a better understanding of this important issue.
